Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7453-7457

  Fang, Ying ^a   Wang, Li ^a   Xia, Guo Hao ^a   Shi, Mei Qi ^a  

^a Jiangsu Tumor Hospital   (China)

Author keywords

Albumin bound paclitaxel; Carboplatin; Cisplatin; Squamous non small cell lung cancer

Indexed keywords

130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUROTOXICITY SYNDROMES; PATHOLOGY; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ALBUMINS; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUROTOXICITY SYNDROMES; PACLITAXEL; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 84907273599     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7453     Document Type: Article

References (15)

1. AaproMS, Minckwitz GV (2008). Molecular basis for the development of noveltaxanes in the treatment of metastatic breast cancer. Eur J Cancer Suppl, 6, 3-l1.
2. Barlesi F, Scherpereel A, Rittmeyer A, et al. (2013). Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol, 31, 3004-11.
3. Ciuleanu T, Brodowicz T, Zielinski C, et al (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer, a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40.
4. Cui L, Liu XX, Jiang Y, et al (2014)Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.
5. Desai N, Trieu V, Damascelli B, et al. (2009). SPARC expression Correlates with tumor response to albumin-bound paclitaxel in headand neck cancerpatients. Transl Oncol, 2, 59-64.
6. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.
7. Gurses N, Topcul M (2013). The effect of abraxane on cell kinetic parameters of HeLa cells. Asian Pac J Cancer Prev, 14, 4229-33.
8. Li XD, Han JC, Zhang YJ, et al (2013). Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8.
9. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6.
10. Ozdemir O, Ozdemir P, Veral A, et al (2013). ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev, 14, 4679-83.
11. Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51.
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
13. Shi YK, Au JS, Thongprasert S, et al. (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 9, 154-62.
14. Socinski MA, Langer CJ, Okamoto I, et al. (2002). Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol, 24, 314-21.
15. Trieu V, Damascelli B, Soon-ShiongP, et al (2008). SPARC expressionin head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007 Abraxane). Washington, DC, the 97th Annual Meetingof the American Association for Cancer Research (AACR), 2006.